Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis
Elevated serum levels of antibodies to carbonic anhydrase I and II in patients with chronic pancreatitis
复制标题
DOI：
10.1097/00006676-200005000-00008
复制
发表时间：
2000-05-01
期刊：
影响因子：
2.9
通讯作者：
Cavallini, G
中科院分区：
文献类型：
--
作者：
Frulloni, L;Bovo, P;Cavallini, G
慢性胰腺炎（CP）的发病机制被认为是对胰腺结构的免疫介导的反应。一些报告表明，在一些患有CP的患者中存在针对胰腺导管上皮的抗体。在特发性CP患者中存在碳酸酐酶I（抗CA I）和II（抗CA II）的血清抗体。本研究的目的是评估一系列CP患者中抗CA I和抗CA II的存在。我们研究了维罗纳大学胰腺研究中心的78例连续CP患者（62例男性，16例女性;平均年龄48.6 ± 10.2岁）。作为对照组，我们研究了从该中心的医疗和护理人员中招募的26名健康受试者。血清抗CA I和抗CA II水平通过酶联免疫吸附试验使用标准方法进行了微小修改。CP患者的抗体平均吸光度高于对照受试者（抗CA I：0.064 +/- 0.042 vs. 0.047 +/- 0.015，p = 0.051;抗CA II：0.038 +/- 0.02 us。0.029 +/- 0.014，p = 0.033）。阳性结果任意定义为抗CA I的吸光度值>0.067，抗CA II的吸光度值> 0.047。我们发现抗CA I和抗CA II阳性分别在78例CP患者中的21例（27%）和78例CP患者中的20例（26%）中，而在26例对照受试者中只有2例（7.7%）（p = 0.032和0.039）。对照组36例受试者中的22例（84.6%）和CP组78例患者中的48例（61.5%）两种抗体检测结果均为阴性（p = 0.03）。对照组无一人和78例CP患者中的12例（16.6%）抗CA I和抗CA II均检测阳性。我们观察到对照组（R = 0.423; p = 0.016）和CP患者（R = 0.584; p < 0.0001）中抗CA I和抗CA II血清水平之间存在显著相关性。血清抗体水平与以下变量之间无相关性：病程、饮酒、吸烟习惯、胰腺手术、胰腺钙化、糖尿病和脂肪肝。部分CP患者血清抗CA I和抗CA II水平升高。
An immune-mediated reaction to pancreatic structures has been postulated for the pathogenesis of chronic pancreatitis (CP). Several reports demonstrate the presence of antibodies to the pancreatic ductal epithelium in some patients suffering from CP. Serum antibodies to carbonic anhydrase I (anti-CA I) and II (anti-CA II) are present in patients affected by idiopathic CP. The aim of this study was to evaluate the presence of anti-CA I and anti-CA II in a series of patients with CP. We studied 78 consecutive CP patients (62 male, 16 female; mean age 48.6 +/- 10.2 years) referred to the Verona University Center for the Study of the Pancreas. As a control group, we studied 26 healthy subjects recruited from among the medical and nursing staff of the center. Serum anti-CA I and anti-CA II levels were quantified by enzyme-linked immunosorbent assay using a standard method with minor modifications. The mean absorbance of antibodies was higher in CP patients than in control subjects (anti-CA I: 0.064 +/- 0.042 vs. 0.047 +/- 0.015, p = 0.051; and anti-CA II: 0.038 +/- 0.02 us. 0.029 +/- 0.014, p = 0.033). Positive results were arbitrarily defined as absorbance values >0.067 for anti-CA I and 0.047 for anti-CA II. We found anti-CA I and anti-CA II positivity in 21 of 78 (27%) and 20 of 78 (26%) of CP patients, respectively, and in only two of 26 control subjects (7.7%) (p = 0.032 and 0.039). Twenty-two of 36 subjects in the control group (84.6%) and 48 of 78 patients (61.5%) in the CP group tested negative For both antibodies (p = 0.03). None of the control subjects and 12 of 78 (16.6%) of the CP patients tested positive for both anti-CA I and anti-CA II. We observed a significant correlation between anti-CA I and anti-CA II serum levels in control subjects (R = 0.423; p = 0.016)and in CP patients (R = 0.584; p < 0.0001). No correlation was found between serum antibody levels and any of the following variables: length of disease, alcohol consumption, smoking habits, pancreatic surgery, pancreatic calcifications, diabetes, and steatorrhea. Serum levels of anti-CA I and anti-CA II are elevated in some patients suffering from CP.